ArticleAntimicrobial agents and chemotherapy2002
Experimental acute otitis media due to nontypeable Haemophilus influenzae: comparison of high and low azithromycin doses with placebo.
Article in Antimicrobial agents and chemotherapy, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 50 citations in OpenAlex.
- Pharmacokinetics, microbial response, and pulmonary outcomes of multidose intravenous azithromycin in preterm infants at risk for Ureaplasma respiratory colonization.Antimicrobial agents and chemotherapy · 2015Trial
- Novel, single-dose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for treatment of mild to moderate community-acquired Pneumonia in adults.Antimicrobial agents and chemotherapy · 2005Trial
- High-dose azithromycin versus high-dose amoxicillin-clavulanate for treatment of children with recurrent or persistent acute otitis media.Antimicrobial agents and chemotherapy · 2003Trial
- Probing Immune-Mediated Clearance of Acute Middle Ear Infection in Mice.Frontiers in cellular and infection microbiology · 2021Article
- Vaccines for Nontypeable Haemophilus influenzae: the Future Is Now.Clinical and vaccine immunology : CVI · 2015Review
- Effect of azithromycin on enhancement of methane production from waste activated sludge.Journal of industrial microbiology & biotechnology · 2014Article
- Variation of pneumococcal Pilus-1 expression results in vaccine escape during Experimental Otitis Media [EOM].PloS one · 2014Article
- Virulence of Streptococcus pneumoniae serotype 6C in experimental otitis media.Microbes and infection · 2012Article
- Nontypeable Streptococcus pneumoniae as an otopathogen.Diagnostic microbiology and infectious disease · 2011Article
- Sialic acid mediated transcriptional modulation of a highly conserved sialometabolism gene cluster in Haemophilus influenzae and its effect on virulence.BMC microbiology · 2010Article
- Role of complement in host defense against pneumococcal otitis media.Infection and immunity · 2009Article
- Article
- Multiple consecutive lavage samplings reveal greater burden of disease and provide direct access to the nontypeable Haemophilus influenzae biofilm in experimental otitis media.Infection and immunity · 2007Article
- Role of complement in defense of the middle ear revealed by restoring the virulence of nontypeable Haemophilus influenzae siaB mutants.Infection and immunity · 2007Article
- Clinical applications of azithromycin microspheres in respiratory tract infections.International journal of nanomedicine · 2007Review
- The chinchilla microdialysis model for the study of antibiotic distribution to middle ear fluid.The AAPS journal · 2006Article
- Study design questions in treatment of children with acute otitis media.Antimicrobial agents and chemotherapy · 2004Article
- Single-dose (30 mg/kg) azithromycin compared with 10-day amoxicillin/clavulanate for the treatment of uncomplicated acute otitis media: a double-blind, placebo-controlled, randomized clinical trial.Current therapeutic research, clinical and experimental · 2003Article
- Single-dose azithromycin for acute otitis media: a pharmacokinetic/pharmacodynamic rationale.Current therapeutic research, clinical and experimental · 2003Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treatment of acute otitis media (AOM) with azithromycin results in apparent clinical success, but tympanocentesis performed 4 to 6 days after initiation of therapy in children with nontypeable Haemophilus influenzae (NTHI) recovered from initial middle ear cultures demonstrates persistence of infection in more than 50% of episodes. We sought to determine the effect of azithromycin at different doses on the density of middle ear infection due to NTHI to provide additional understanding of this dichotomy between clinical and microbiologic outcome measures in AOM. In a chinchilla model of experimental otitis media (EOM), animals treated with placebo were compared to animals receiving a single daily dose 30 or 120 mg of azithromycin per kg of body weight per day for 5 days. Microbiologic outcome was assessed by obtaining quantitative cultures from the middle ear during a 5-day course and for 1 week following therapy. Azithromycin concentrations were measured to ascertain whether a concentration-dependent effect was present. Azithromycin at 30 and 120 mg/kg/day demonstrated a dose-dependent effect on the quantitative assessment of middle ear infection due to NTHI. A 30-mg/kg dose of azithromycin daily resulted in levels in serum and areas under the serum concentration-time curve at 24 h comparable to published data obtained with children given azithromycin at 5 to 10 mg/kg in multiday regimens. Increased doses of azithromycin (120 mg/kg) achieved 2.5- to 4-fold-higher levels in serum and 3- to 6-fold-higher total levels and levels in extracellular middle ear fluid as well as more rapid reduction in bacterial density and a greater proportion of middle ears with complete sterilization than either placebo or the 30-mg/kg/day regimen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.